Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens-Reference-Cited by-同舟云学术

Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens

Published:2014-02 Issue:2 Volume:32 Page:70-79
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Saad Fred,Miller Kurt

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference82 articles.

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: IARC, 〈http://globocan.iarc.fr〉 [accessed 2.05.12].

2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology–Prostate Cancer, V2.2012, 〈www.nccn.org〉 [accessed 27.03.12].

3. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

4. Novel strategies in the treatment of castration-resistant prostate cancer;Marech;Int J Oncol,2012

5. Castration-resistant prostate cancer: systemic therapy in 2012;Maluf;Clinics,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer;Cancers;2022-12-06

2. Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors;Cells;2022-09-07

3. The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines;International Journal of Molecular Sciences;2020-12-16

4. Pharmacokinetic drug–drug interactions: an insight into recent US FDA-approved drugs for prostate cancer;Bioanalysis;2020-11

5. EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells;Colloids and Surfaces B: Biointerfaces;2020-10